Baxter's HemAssist cleared for trauma trial
This article was originally published in Clinica
Executive Summary
Baxter Healthcare's HemAssist has been cleared by the FDA to begin a Phase III trial in the US. The purpose of the trial is to investigate the effect of the liquid on survival in patients suffering severe trauma. HemAssist is an oxygen-carrying liquid which is used as a temporary substitute for lost blood. It restores blood pressure and increases oxygen delivery in patients suffering from blood loss and shock caused by severe trauma.